Allergan's OZURDEX Gets European Positive Opinion For Treating DME

(RTTNews) - Allergan Inc. (AGN) Friday said the European Union's Committee for Medicinal Products for Human Use or CHMP has proposed extending the marketing authorization for OZURDEX, to treat adult patients with vision loss due to diabetic macular edema or DME. Allergan is still awaiting the final decision from the European Commission, which is expected within a few months.

The CHMP is the scientific committee of the European Medicines Agency which recommends medicines for marketing authorization across the 28 member states of the European Union.

Currently, OZURDEX is available throughout the European Union as a treatment, licensed for macular edema in patients with retinal vein occlusion and for inflammation of the posterior segment of the eye characterized as non-infectious uveitis.